Stockscreener 앱 받기
59.87
0.12%
-0.07
전일 마감가:
$59.94
열려 있는:
$59.94
하루 거래량:
1.94M
Relative Volume:
0.74
시가총액:
$11.50B
수익:
$2.95B
순이익/손실:
$523.88M
주가수익비율:
22.26
EPS:
2.69
순현금흐름:
$620.18M
1주 성능:
+2.99%
1개월 성능:
+8.46%
6개월 성능:
+2.69%
1년 성능:
-7.06%
1일 변동 폭
$59.45
$60.99
1주일 범위
$57.32
$61.48
52주 변동 폭
$50.76
$73.51
바이오마린 Stock (BMRN) Company Profile
명칭
Biomarin Pharmaceutical Inc
전화
(415) 506-6700
주소
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
59.87 | 11.52B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
바이오마린 Stock (BMRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2026-01-20 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2025-12-03 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-09-08 | 개시 | H.C. Wainwright | Neutral |
| 2025-09-03 | 개시 | Raymond James | Outperform |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-02-24 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-30 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-20 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | 개시 | Evercore ISI | Outperform |
| 2023-11-15 | 개시 | Wells Fargo | Overweight |
| 2023-10-23 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | 개시 | Raymond James | Mkt Perform |
| 2023-09-18 | 개시 | UBS | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-07-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2023-02-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-02-21 | 개시 | Citigroup | Neutral |
| 2023-01-30 | 개시 | BMO Capital Markets | Market Perform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2022-10-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2022-04-25 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-09-09 | 업그레이드 | Stifel | Hold → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-04 | 재개 | Guggenheim | Buy |
| 2021-03-01 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-08-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2020-08-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | 재확인 | Citigroup | Buy |
| 2020-01-28 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-27 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-24 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-04-09 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-07 | 재확인 | Stifel | Buy |
| 2018-08-03 | 재확인 | Stifel | Buy |
모두보기
바이오마린 주식(BMRN)의 최신 뉴스
LSV Asset Management Purchases 812,284 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Baird maintains BioMarin stock rating amid competitor’s positive trial data By Investing.com - Investing.com Nigeria
Looking To Compete With BioMarin, Ascendis Continues Its Growth Story - Citeline News & Insights
BioMarin Raises $850 Million Notes for Amicus Acquisition - TipRanks
BioMarin Signs Indenture For Senior Notes With U.S. Bank Trust Company - TradingView
BioMarin finances Amicus acquisition with $850M notes and new loans - Stock Titan
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - Bitget
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - Benzinga
BioMarin Pharmaceutical, Amicus Therapeutics deal gets early termination from US FTC - MLex
BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis - BioPharma Dive
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Finviz
Baird maintains BioMarin stock rating amid competitor’s positive trial data - Investing.com
BioMarin, Ascendis stocks fall after BridgeBio’s positive achondroplasia data By Investing.com - Investing.com UK
BridgeBio's oral drug boosts growth in children with dwarfism in late-stage trial - Reuters
BioMarin Bet on Amicus To Ease Voxzogo’s Decline. Will It Work? - BioSpace
Pharma companies left out of Trump's drug-pricing deals look for way in - marketscreener.com
Earnings Preview: BioMarin Pharmaceutical (BMRN) Q4 Earnings Expected to Decline - Finviz
Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings? - Finviz
Why BioMarin Pharmaceutical Inc. stock is a must watch in 2025Trade Exit Summary & Verified Momentum Watchlists - mfd.ru
Biomarin receives Health Canada notice of compliance with conditions for Voxzogo, for achondroplasia - marketscreener.com
BioMarin receives Health Canada Notice of Compliance with conditions for VOXZOGO®, for Achondroplasia - Newswire Canada
BioMarin Pharmaceutical (BMRN) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Is BioMarin Pharmaceutical (BMRN) Now Trading Below Its Long Term Prospects - Sahm
Will BioMarin Pharmaceutical Inc. stock maintain growth storyJuly 2025 Trends & Stepwise Entry and Exit Trade Signals - mfd.ru
Acquisition plans to fuel BioMarin Pharmaceutical (BMRN), according to Barclays - MSN
What Does the Street Think About BioMarin Pharmaceutical Inc. (BMRN)? - Finviz
BioMarin Pharmaceutical Stock Outlook Looks Promising - Intellectia AI
BioMarin’s Strategic Acquisition Nears Critical Data Readout - AD HOC NEWS
Acquisition Plans to Fuel BioMarin Pharmaceutical (BMRN), According to Barclays - Finviz
A Look At BioMarin Pharmaceutical (BMRN) Valuation After Recent Share Price Momentum - Sahm
Assessing BioMarin Pharmaceutical: Insights From 5 Financial Analysts - Benzinga
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Lowered to $84.00 at Piper Sandler - MarketBeat
The Best Biotech Stocks to Buy - Morningstar
The Top 12 Companies Hiring in Biopharma Now - BioSpace
Callan Family Office LLC Has $2.27 Million Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Achondroplasia Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | BioMarin Pharmaceuticals, BridgeBio/ QED Therapeutics, Ribomic Inc, Sanofi - Barchart.com
AlphaQuest LLC Sells 21,696 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Sues Zydus to Block Copy of Dwarfism Drug Voxzogo - Bloomberg Law News
BioMarin Pharmaceutical Inc. (BMRN): Investor Outlook on a Biotech Leader with 60% Upside Potential - DirectorsTalk Interviews
BioMarin lines up $850m bond sale to finance Amicus takeover - The Pharma Letter
California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare-disease company with a presence in Philadelphia - MSN
(BMRN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
The Right Play On BioMarin Pharmaceuticals (NASDAQ:BMRN) - Seeking Alpha
BioMarin Pharmaceutical Inc. $BMRN Shares Purchased by Federated Hermes Inc. - MarketBeat
Investors Holding Back On BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - 富途牛牛
Should You Buy BioMarin Pharmaceutical Before Feb. 18? - Finviz
BioMarin prices $850 million in senior notes to fund Amicus acquisition - Investing.com India
BioMarin Secures Major Debt Financing for Amicus Acquisition - TipRanks
BioMarin Pharmaceutical Inc Announces Pricing of Senior Notes and Loan Syndication - TradingView
BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility - Chartmill
Hussman Strategic Advisors Inc. Takes $1.14 Million Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
바이오마린 (BMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):